

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1.-45. (Cancelled)

46. (Currently Amended) A pharmaceutical aerosol formulation comprising a hydrofluoroalkane (HFA) propellant; a physiologically effective amount of a medicament for inhalation; and an alkyl saccharide surfactant, wherein the medicament and the surfactant are in ~~particle form~~ suspended in the propellant as a finely divided powder.

47.-53. (Cancelled)

54. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 46, wherein the surfactant is selected from the group consisting of an alkyl glucoside and an alkyl maltoside.

55. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 54, wherein the surfactant is selected from the group consisting of decyl glucoside and dodecyl maltoside.

56. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 46, wherein the formulation comprises a propellant selected from the group consisting of

1,1,1,2-tetrafluoroethane (P134a), 1,1,1,2,3,3,3-heptafluoropropane (P227), or 1,1-difluoroethane (P152a).

57. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 56, wherein the formulation comprises a propellant mixture comprising 1,1,1,2-tetrafluoroethane (P134a) and 1,1,1,2,3,3,3-heptafluoropropane (P227).

58. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 57, wherein the formulation comprises a density-matched propellant mixture of 1,1,1,2-tetrafluoroethane (P134a) and 1,1,1,2,3,3,3-heptafluoropropane (P227).

59. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 46, wherein the medicament is selected from the group consisting of a  $\beta$ 2-adrenoreceptor agonist, an anticholinergic bronchodilator, and a glucocorticosteroid.

60. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 46, wherein the medicament is selected from the group consisting of salbutamol, terbutaline, rimiterol, fenoterol, reproterol, adrenaline, pirbuterol, isoprenaline, orciprenaline, bitolterol, salmeterol, formoterol, clenbuterol, procaterol, broxaterol, picumeterol, mabuterol, ipratropium bromide, beclomethasone, fluticasone, budesonide, tipredane, dexamethasone, betamethasone, fluocinolone, triamcinolone acetonide, mometasone, and pharmacologically acceptable esters and salts thereof.

61. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 46, wherein the medicament is selected from the group consisting of anti-allergic

medicaments, expectorants, mucolytics, antihistamines, cyclooxygenase inhibitors, leukotriene synthesis inhibitors, leukotriene antagonists, phospholipase-A2 (PLA2) inhibitors, platelet aggregating factor (PAF) antagonists, prophylactics of asthma, antiarrhythmic medicaments, tranquilisers, cardiac glycosides, hormones, anti-hypertensive medicaments, antidiabetic medicaments, antiparasitic medicaments, anticancer medicaments, sedatives, analgesic medicaments, antibiotics, antirheumatic medicaments, immunotherapeutic agents, antifungal medicaments, antihypotension medicaments, vaccines, antiviral medicaments, proteins, peptides, vitamins, cell surface receptor blockers, antioxidants, free radical scavengers, and organic salts of N,N'-diacetylcystine.

62. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 46, including ethanol in an amount of up to 20% by weight of propellant and surfactant.

63. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 46, including ethanol in an amount of up to 5% by weight of propellant and surfactant.

64. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 46, further comprising a substance selected from the group consisting of adjuvants, carriers, flavouring agents, buffers, antioxidants and chemical stabilisers.

65. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 46, wherein at least 50% of the medicament consists of particles having a diameter of 0.01-10 microns.

66. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 46, wherein at least 50% of the medicament consists of particles having a diameter of 0.1-6 microns.

67. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 46, wherein at least 50% of the medicament consists of particles having a diameter of 0.1-5 microns.

68. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 65, wherein at least 70% of the medicament consists of particles having a diameter of 0.01-10 microns.

69. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 65, wherein at least 90% of the medicament consists of particles having a diameter of 0.01-10 microns.

70. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 66, wherein at least 70% of the medicament consists of particles having a diameter of 0.01-6 microns.

71. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 66, wherein at least 90% of the medicament consists of particles having a diameter of 0.01-6 microns.

72. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 46, wherein the concentration of medicament in the formulation is 0.1 mg/ml to 25 mg/ml.

73. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 46, wherein the ratio of surfactant to medicament is in the range of 1:50 to 1:0.2.

74. (Currently Amended) A method for the manufacture of a pharmaceutical aerosol formulation as claimed in claim 46, comprising the steps of:

providing a mixture of the medicament and the surfactant in a vessel;  
adding hydrofluoroalkane (HFA) propellant to the vessel; and  
mixing the propellant with the medicament/surfactant mixture to produce a medicament/surfactant/propellant mixture.

75. (Currently Amended) The method of claim 74, further comprising the step of mixing additional HFA propellant with the medicament/surfactant/propellant mixture.

76. (Currently Amended) A method for the treatment of a patient in need of therapy with an inhaled medicament, comprising administering to said patient a therapeutically effective amount of a pharmaceutical aerosol formulation comprising a HFA propellant; a physiologically effective amount of ~~the~~ a medicament for inhalation; and an alkyl saccharide surfactant, wherein the medicament and the surfactant are ~~in particle form~~ suspended in the propellant as a finely divided powder.

77. (Previously Presented) The method of claim 76, wherein the formulation comprises a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane (P134a), 1,1,1,2,3,3,3-heptafluoropropane (P227), and 1,1-difluoroethane (P152a).

78.-79. (Cancelled)

80. (Previously Presented) The method of claim 76, wherein the surfactant is selected from the group consisting of an alkyl glucoside and an alkyl maltoside.

81. (Previously Presented) The method of claim 76, wherein the medicament is selected from the group consisting of a  $\beta$ 2-adrenoreceptor agonist, an anticholinergic bronchodilator, and a glucocorticosteroid.

82. (Previously Presented) The method of claim 76, wherein the medicament is selected from the group consisting of anti-allergic medicaments, expectorants, mucolytics, antihistamines, cyclooxygenase inhibitors, leukotriene synthesis inhibitors, leukotriene antagonists, phospholipase-A2 (PLA2) inhibitors, platelet aggregating factor (PAF) antagonists, prophylactics of asthma, antiarrhythmic medicaments, tranquilisers, cardiac glycosides, hormones, anti-hypertensive medicaments, antidiabetic medicaments, antiparasitic medicaments, anticancer medicaments, sedatives, analgesic medicaments, antibiotics, antirheumatic medicaments, immunotherapeutic agents, antifungal medicaments, antihypotension medicaments, vaccines, antiviral medicaments, proteins, peptides, vitamins, cell surface receptor blockers, antioxidants, free radical scavengers, and organic salts of N,N'-diacetylcystine.

83. (Previously Presented) The method of claim 76, wherein the ratio of surfactant to medicament is in the range of 1:50 to 1:0.2.

84. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 46, the formulation comprising a physiologically effective amount of each of a  $\beta$ 2-adrenoreceptor agonist and a glucocorticosteroid.

85. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 84, further comprising a physiologically effective amount of an anticholinergic bronchodilator.

86. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 46, the formulation comprising a physiologically effective amount of each of (a) formoterol, or a salt, ester, solvate, or solvate of a salt or ester thereof; and (b) budesonide, or a salt, ester, solvate, or solvate of a salt or ester thereof.

87. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 46, the formulation comprising a physiologically effective amount of each of (a) formoterol, or a salt, ester, solvate, or solvate of a salt or ester thereof; and (b) mometasone, or a salt ester, solvate, or solvate of a salt or ester therefor.

88. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 46, the formulation comprising a physiologically effective amount of each of (a) formoterol, or a salt, ester, solvate, or solvate of a salt or ester thereof; and (b) fluticasone, or a salt, ester, solvate, or solvate of a salt or ester thereof.

89. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 46, the formulation comprising a physiologically effective amount of each of (a)

salmeterol, or a salt, ester, solvate, or solvate of a salt or ester thereof; and (b) fluticasone, or a salt, ester, solvate, or solvate of a salt or ester thereof.

90. (Previously Presented) The method of claim 76, wherein the formulation comprises a physiologically effective amount of each of a  $\beta$ 2-adrenoreceptor agonist and a glucocorticosteroid.

91. (Previously Presented) The method of claim 90, wherein the formulation further comprises a physiologically effective amount of an anticholinergic bronchodilator.

92. (Previously Presented) The method of claim 76, wherein the formulation comprises a physiologically effective amount of each of (a) formoterol, or a salt, ester, solvate, or solvate of a salt or ester thereof; and (b) budesonide, or a salt, ester, solvate, or solvate of a salt or ester thereof.

93. (Previously Presented) The method of claim 76, wherein the formulation comprises a physiologically effective amount of each of (a) formoterol, or a salt, ester, solvate, or solvate of a salt or ester thereof; and (b) mometasone, or a salt ester, solvate, or solvate of a salt or ester therefor.

94. (Previously Presented) The method of claim 76, wherein the formulation comprises a physiologically effective amount of each of (a) formoterol, or a salt, ester, solvate, or solvate of a salt or ester thereof; and (b) fluticasone, or a salt, ester, solvate, or solvate of a salt or ester thereof.

95. (Previously Presented) The method of claim 76, wherein the formulation comprises a physiologically effective amount of each of (a) salmeterol, or a salt, ester, solvate, or



solvate of a salt or ester thereof; and (b) fluticasone, or a salt, ester, solvate, or solvate of a salt or ester thereof.

96. (Previously Presented) The pharmaceutical aerosol formulation as claimed in claim 46, wherein the surfactant is decyl glucoside.

97. (Previously Presented) The pharmaceutical aerosol formulation as claimed in claim 46, wherein the surfactant is dodecyl maltoside.

98. (Previously Presented) The pharmaceutical aerosol formulation as claimed in claim 56, wherein the surfactant is decyl glucoside.

99. (Previously Presented) The pharmaceutical aerosol formulation as claimed in claim 56, wherein the surfactant is dodecyl maltoside.

100. (Previously Presented) The pharmaceutical aerosol formulation as claimed in claim 57, wherein the surfactant is decyl glucoside.

101. (Previously Presented) The pharmaceutical aerosol formulation as claimed in claim 57, wherein the surfactant is dodecyl maltoside.

102. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 46, the formulation comprising a physiologically effective amount of each of (a) formoterol and (b) budesonide.

103. (Previously Presented) The method of claim 76, wherein the formulation comprises a physiologically effective amount of each of (a) formoterol and (b) budesonide.

104. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 46, wherein the formulation comprises a physiologically effective amount of each of (a) an anticholinergic bronchodilator and (b) a  $\beta$ 2-adrenoreceptor agonist.

105. (Previously Presented) A pharmaceutical aerosol formulation as claimed in claim 46, wherein the formulation comprises a physiologically effective amount of each of (a) an anticholinergic bronchodilator and (b) a glucocorticosteroid.

106. (Previously Presented) The method of claim 76, wherein the formulation comprises a physiologically effective amount of each of (a) an anticholinergic bronchodilator and (b) a  $\beta$ 2-adrenoreceptor agonist.

107. (Previously Presented) The method of claim 76, wherein the formulation comprises a physiologically effective amount of each of (a) an anticholinergic bronchodilator and (b) a glucocorticosteroid.